EQS-News: Sartorius completes acquisition of MatTek

01.07.25 17:30 Uhr

Werte in diesem Artikel
Aktien

216,20 EUR -1,70 EUR -0,78%

EQS-News: SARTORIUS AG / Key word(s): Mergers & Acquisitions
Sartorius completes acquisition of MatTek (news with additional features)

01.07.2025 / 17:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

Wer­bung


Göttingen, Germany | July 1, 2025

Sartorius completes acquisition of MatTek

The life science group Sartorius has successfully closed the acquisition of MatTek Corp, including Visikol Inc, from the Swedish BICO Group AB, as announced in April. The acquisition was completed on July 1, 2025, following the receipt of the required regulatory approval and the fulfillment of other customary closing conditions. With the integration of the business into its Lab Products and Services division, Sartorius is expanding its cell technology portfolio and creating synergies with existing solutions for drug development, including cell analysis instruments, reagents, and AI models.
 
MatTek is a leading developer and manufacturer of human cell-based microtissues and 3D models that accelerate drug development. The advanced cell models mimic the structure and function of human tissue and deliver more accurate, cost-effective, and reproducible results compared to traditional 2D cell cultures, while reducing the need for animal testing. The company employs more than 80 people at its headquarters in Ashland, Massachusetts, USA, and at its production site in Bratislava, Slovakia.
A profile of Sartorius
Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. Around 13,500 employees are working for customers around the globe. 

Visit our Newsroom and follow Sartorius on LinkedIn.
Contact
Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com

Additional features:

File: Sartorius completes acquisition of MatTek | Media Release


01.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SARTORIUS AG
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: info@sartorius.com
Internet: www.sartorius.com
ISIN: DE0007165631, DE0007165607
WKN: 716563, 716560
Indices: DAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2162694

 
End of News EQS News Service

Wer­bung

2162694  01.07.2025 CET/CEST

Ausgewählte Hebelprodukte auf Sartorius vz.

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sartorius vz.

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Sartorius AG Vz.

Wer­bung

Analysen zu Sartorius AG Vz.

DatumRatingAnalyst
24.06.2025Sartorius vz OverweightJP Morgan Chase & Co.
18.06.2025Sartorius vz OverweightBarclays Capital
13.06.2025Sartorius vz HoldJefferies & Company Inc.
06.06.2025Sartorius vz NeutralUBS AG
21.05.2025Sartorius vz Sector PerformRBC Capital Markets
DatumRatingAnalyst
24.06.2025Sartorius vz OverweightJP Morgan Chase & Co.
18.06.2025Sartorius vz OverweightBarclays Capital
25.04.2025Sartorius vz OverweightJP Morgan Chase & Co.
17.04.2025Sartorius vz BuyDeutsche Bank AG
26.03.2025Sartorius vz OverweightJP Morgan Chase & Co.
DatumRatingAnalyst
13.06.2025Sartorius vz HoldJefferies & Company Inc.
06.06.2025Sartorius vz NeutralUBS AG
21.05.2025Sartorius vz Sector PerformRBC Capital Markets
12.05.2025Sartorius vz HoldJefferies & Company Inc.
23.04.2025Sartorius vz HoldJefferies & Company Inc.
DatumRatingAnalyst
29.01.2025Sartorius vz VerkaufenDZ BANK
28.01.2025Sartorius vz UnderperformBernstein Research
15.01.2025Sartorius vz UnderperformBernstein Research
06.01.2025Sartorius vz UnderperformBernstein Research
06.01.2025Sartorius vz UnderperformBernstein Research

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sartorius AG Vz. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen